Microbicide Trials Network
CLARIFICATION MEMO #01 TO:

MTN-003
DAIDS Document ID #10622

Phase 2B Safety and Effectiveness Study of Tenofovir 1% Gel, Tenofovir Disoproxil Fumarate Tablet and Emtricitabine/Tenofovir Disoproxil Fumarate Tablet for the Prevention of HIV Infection in Women

Version 2.0 / 31 December 2010
IND #: 55,690

Date of Clarification Memorandum: 27 October 2011

Section 1: Summary of Clarifications and Rationale

The items clarified in this Clarification Memorandum (CM) have been approved by the NIAID Medical Officer and are to be implemented immediately upon issuance. Institutional Review Board/Ethics Committee (IRB/EC) approval of this CM is not required by the sponsor; however, investigators may submit the CM to the IRB/EC overseeing the study at their site for information. This CM is official MTN-003 documentation and is effective immediately. A copy of this CM must be retained in each study site’s Essential Documents file for MTN-003. No change in informed consent is necessitated by or included in this CM.

This CM provides clarification on the following items:

1. Updates to Protocol Team Roster, to reflect changes to the Protocol Team
2. New name for Study Operations Center (FHI 360)
3. Update to Clinical and Laboratory Procedures, with corresponding updates to Appendix I: Schedule of Study Visits

Section 2: Implementation

With the exception of the modifications to the Protocol Team Roster, text to be deleted is noted by strikethrough and text to be added is noted below in bold.

1. The Protocol Team Roster is updated to include changes to Site Investigators.

Nicola Coumi, MMed Sci
Site Investigator
MRC – HPRU
P.O. Box 70380
Overport, KwaZulu-Natal 4067 South Africa
Phone: 27-31-242-3709
Fax: 27-31-242-3800
Email: Nicola.Coumi@MRC.ac.za

Arendevi Pather, B. Pharm.
Site Investigator
MRC – HPRU
P.O. Box 70380
Overport, KwaZulu-Natal 4067 South Africa
Phone: 27-31-242-3644
Fax: 27-31-242-3800
Email: apather@MRC.ac.za
The following individuals have been removed from the Protocol Team Roster: Shahnaaz Kadwa, Kathy Mngadi, Vimla Naicker, Linda Zako.

2. References to FHI have been changed to FHI 360 throughout the document. Email addresses ending in fhi.org have been changed to fhi360.org throughout the document.

3. In Section 7.5.2, Clinical Procedures, the following update is made under the ninth sub-bullet of the fourth bullet, regarding Pap smear:

- ecto- and endocervical cells for Pap smear (at selected sites):
  - At PUEV, **when clinically indicated**
  - When clinically indicated and/or per local clinical guidelines

The corresponding update (addition of ▲•, to specify “as indicated, at sites with capacity where local standard of care”) is made to Appendix I in the column for PUEV:

| Pap Smear | ▲• | ▲• | ▲• | ▲• | ▲• | ▲• | ▲• | ▲• |

In Section 7.5.3, Laboratory Procedures, the timing of PBMC archive is clarified:

- PBMC archive (for consenting participants at selected sites approved by NL)
  - At the first quarterly visit following consent and every six months thereafter, during scheduled study participation
  - **At PUEV**
  - As indicated (**including** in Section 7.6.1)

The following table in Appendix I was updated to include clarifications to Section 7.5.3:
# SCHEDULE OF PBMC COLLECTION

<table>
<thead>
<tr>
<th></th>
<th>First QRT</th>
<th>Q 6 Months</th>
<th>INT</th>
<th>PUEV</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBMC Collection at Sites with NL Approval</td>
<td>X*</td>
<td>X</td>
<td>▲</td>
<td>X</td>
</tr>
<tr>
<td>TFV-DP and FTC-TP Levels</td>
<td>X*</td>
<td>X</td>
<td>▲</td>
<td>X</td>
</tr>
</tbody>
</table>

*Applies to the participant’s first QRT visit following consent for PBMC collection, then every six months thereafter during study participation, **plus PUEV**.

▲ If a scheduled collection is missed, PBMC should be collected at the next completed visit (scheduled or interim), unless the next visit is less than 4 weeks away from the next scheduled PBMC collection, (in which case collection could **should** occur at the latter visit). Participants who are temporarily held or permanently discontinued from study product should continue to have scheduled PBMC collection unless otherwise specified in the MTN-003 SSP Manual.

The above information will be incorporated into the next version of the protocol at a later time if it is amended.